MX2021010834A - Compuesto y metodo para la prevencion de transmision del virus de influenza. - Google Patents
Compuesto y metodo para la prevencion de transmision del virus de influenza.Info
- Publication number
- MX2021010834A MX2021010834A MX2021010834A MX2021010834A MX2021010834A MX 2021010834 A MX2021010834 A MX 2021010834A MX 2021010834 A MX2021010834 A MX 2021010834A MX 2021010834 A MX2021010834 A MX 2021010834A MX 2021010834 A MX2021010834 A MX 2021010834A
- Authority
- MX
- Mexico
- Prior art keywords
- compound
- influenza
- patient
- influenza virus
- index
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La presente invención se relaciona con un método para evitar la transmisión de influenza, en donde el método comprende administrar una cantidad eficaz de un compuesto a un paciente que tiene infección por virus de influenza, en la presente denominado como "paciente índice", en donde el compuesto tiene una de las fórmulas (I) y (II), o su sal farmacéuticamente aceptable. El compuesto que va a ser usado en la presente invención reduce la infectividad del virus de la influenza del paciente índice, y por lo tanto reduce el riesgo de que el paciente índice active una epidemia de influenza o una pandemia de influenza en comparación con un paciente control. Por lo tanto, un aspecto de la presente invención se relaciona con un método para evitar una epidemia de influenza o una pandemia de influenza, en donde el método comprende administrar una cantidad eficaz de un compuesto a pacientes que presentan infección por virus de influenza (pacientes índice), en donde el compuesto se administra a por lo menos 10% de todas las personas infectadas con influenza de una ciudad o la población de un país, y en donde el compuesto tiene una de las fórmulas (I) y (II) o es una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19166228.7A EP3714889A1 (en) | 2019-03-29 | 2019-03-29 | Baloxavir for the prevention of transmission of influenza virus |
| PCT/EP2020/058573 WO2020201019A1 (en) | 2019-03-29 | 2020-03-26 | Compound and method for the prevention of transmission of influenza virus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021010834A true MX2021010834A (es) | 2021-10-14 |
Family
ID=66041247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021010834A MX2021010834A (es) | 2019-03-29 | 2020-03-26 | Compuesto y metodo para la prevencion de transmision del virus de influenza. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11389457B2 (es) |
| EP (2) | EP3714889A1 (es) |
| JP (1) | JP2022526366A (es) |
| KR (1) | KR20210146992A (es) |
| CN (1) | CN113784719A (es) |
| AU (1) | AU2020254906A1 (es) |
| BR (1) | BR112021014421A2 (es) |
| CA (1) | CA3129668A1 (es) |
| IL (1) | IL284990A (es) |
| MX (1) | MX2021010834A (es) |
| TW (1) | TW202102227A (es) |
| WO (1) | WO2020201019A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112542250A (zh) * | 2020-11-04 | 2021-03-23 | 温州大学 | 基于优化seird模型的全球新冠病毒传播预测方法 |
| CN114601803B (zh) * | 2020-12-07 | 2023-08-01 | 谢斌 | 一种巴洛沙韦酯干混悬剂及其制备方法和应用 |
| KR20230062080A (ko) | 2021-10-29 | 2023-05-09 | 코웨이 주식회사 | 냉수 탱크 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7166435B2 (en) * | 2001-08-06 | 2007-01-23 | The Quigley Corporation | Compositions and methods for reducing the transmissivity of illnesses |
| WO2010147068A1 (ja) | 2009-06-15 | 2010-12-23 | 塩野義製薬株式会社 | 置換された多環性カルバモイルピリドン誘導体 |
| DK2620436T3 (en) | 2010-09-24 | 2018-07-30 | Shionogi & Co | Substituted polycyclic carbamoylpyridone derivative prodrug |
| DK3428170T3 (da) | 2015-04-28 | 2021-03-01 | Shionogi & Co | Anti-influenza polycyklisk pyridonderivat og prodrug deraf |
| JP6323860B2 (ja) | 2015-12-15 | 2018-05-16 | 塩野義製薬株式会社 | キャップ依存的エンドヌクレアーゼ阻害剤及び抗インフルエンザ薬を組み合わせることを特徴とするインフルエンザ治療用医薬 |
| NZ750052A (en) | 2016-08-10 | 2024-08-30 | Shionogi & Co Ltd | Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof |
| TWI795462B (zh) * | 2017-11-17 | 2023-03-11 | 日商鹽野義製藥股份有限公司 | 光安定性及溶出性優異的醫藥製劑 |
| WO2020058745A1 (en) | 2018-09-18 | 2020-03-26 | Shionogi & Co., Ltd. | Treating influenza using substituted polycyclic pyridone derivatives and prodrugs thereof |
| AU2019433734A1 (en) * | 2019-03-12 | 2021-09-30 | Shionogi & Co., Ltd. | Treating influenza using substituted polycyclic pyridone derivatives and prodrugs thereof in a subject having influenza and a complication risk factor |
| US20220008429A2 (en) | 2019-03-22 | 2022-01-13 | Shionogi & Co., Ltd. | Treating influenza using substituted polycyclic pyridone derivatives and prodrugs thereof in a subject having influenza and a severe influenza condition |
| US20210069204A1 (en) | 2019-08-13 | 2021-03-11 | F. Hoffmann-La Roche Ag | Dosage of baloxavir marboxil for pediatric patients |
| KR20220045199A (ko) | 2019-08-13 | 2022-04-12 | 에프. 호프만-라 로슈 아게 | 소아 환자를 위한 발록사비르 마르복실의 개선된 투여량 |
-
2019
- 2019-03-29 EP EP19166228.7A patent/EP3714889A1/en active Pending
-
2020
- 2020-03-26 KR KR1020217035209A patent/KR20210146992A/ko unknown
- 2020-03-26 BR BR112021014421-8A patent/BR112021014421A2/pt unknown
- 2020-03-26 TW TW109110208A patent/TW202102227A/zh unknown
- 2020-03-26 AU AU2020254906A patent/AU2020254906A1/en active Pending
- 2020-03-26 US US16/830,764 patent/US11389457B2/en active Active
- 2020-03-26 MX MX2021010834A patent/MX2021010834A/es unknown
- 2020-03-26 JP JP2021557775A patent/JP2022526366A/ja active Pending
- 2020-03-26 EP EP20713011.3A patent/EP3946356A1/en active Pending
- 2020-03-26 CA CA3129668A patent/CA3129668A1/en active Pending
- 2020-03-26 WO PCT/EP2020/058573 patent/WO2020201019A1/en unknown
- 2020-03-26 CN CN202080025834.1A patent/CN113784719A/zh active Pending
-
2021
- 2021-07-20 IL IL284990A patent/IL284990A/en unknown
- 2021-12-23 US US17/560,501 patent/US11911394B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11911394B2 (en) | 2024-02-27 |
| KR20210146992A (ko) | 2021-12-06 |
| IL284990A (en) | 2021-09-30 |
| CN113784719A (zh) | 2021-12-10 |
| JP2022526366A (ja) | 2022-05-24 |
| BR112021014421A2 (pt) | 2021-10-05 |
| EP3714889A1 (en) | 2020-09-30 |
| AU2020254906A1 (en) | 2021-08-19 |
| CA3129668A1 (en) | 2020-10-08 |
| WO2020201019A1 (en) | 2020-10-08 |
| EP3946356A1 (en) | 2022-02-09 |
| US11389457B2 (en) | 2022-07-19 |
| US20220331331A1 (en) | 2022-10-20 |
| US20200330473A1 (en) | 2020-10-22 |
| TW202102227A (zh) | 2021-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021010834A (es) | Compuesto y metodo para la prevencion de transmision del virus de influenza. | |
| SA521430792B1 (ar) | مركبات مضادة للفيروسات محتوية على نيتريل | |
| BR112022026899A2 (pt) | Composto representado pela fórmula (i) ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método de tratamento ou prevenção de uma infecção por vírus, método de inibição da protease 3c viral ou protease 3cl viral em um mamífero e método de tratamento de um distúrbio respiratório | |
| MX2022012714A (es) | Inhibidores de la replicacion de norovirus y coronavirus. | |
| ZA202208947B (en) | Highly active compounds against covid-19 | |
| WO2021207409A3 (en) | Small molecule inhibitors of sars-cov-2 viral replication and uses thereof | |
| WO2006044968A3 (en) | Combination therapy for treating viral infections | |
| WO2005020884A3 (en) | Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses | |
| SI2932970T1 (en) | Antiviral therapy | |
| MD4430C1 (ro) | Compoziţii şi metode de tratament al hepatitei virale C | |
| MX2022011111A (es) | Métodos para tratar infección de coronavirus y lesión pulmonar inducida por inflamación resultante. | |
| ES2570401T3 (es) | Métodos de tratamiento usando dosis únicas de oritavancina | |
| RU2011127080A (ru) | Производное циклоспорина для применения в лечении заражения вирусом гепатита с и вич | |
| MX2024006396A (es) | Compuestos terapeuticos para la infeccion por el virus de inmunodeficiencia humana (vih). | |
| WO2021173713A8 (en) | Highly active compounds against covid-19 | |
| MX2022006742A (es) | Uso y composicion farmaceutica de derivados de fenilisoxazolil metilen-naftaleno-eter. | |
| MX2021009219A (es) | Triamtereno o nolatrexed para su uso en el tratamiento de la fenilcetonuria. | |
| WO2005097618A3 (en) | Low dose therapy for treating viral infections | |
| MX2022013722A (es) | Cisteamina para el tratamiento de infección por sars-cov-2. | |
| ATE192926T1 (de) | Flavopereirine enthaltende zusammensetzung und ihre anwendung in der behandlung gegen hiv-viren | |
| US11724077B2 (en) | Therapeutic swabs for treating upper respiratory infections | |
| WO2021188614A9 (en) | Composition, methods of making and using for treating a viral infection, including coronavirus infection | |
| RU2013129824A (ru) | Новое лечение инфекции вируса гепатита с | |
| DE60025826D1 (de) | Pyrazolidinol-verbindungen | |
| DK1143976T3 (da) | Beta-D-2', 3'-didehydro-2', 3'-dideoxy-5-fluorcytidin til anvendelse i behandlingen af HIV-infektioner |